Cord Blood Transplantation for Multiple Myeloma: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation - Tập 21 - Trang 1291-1298 - 2015
Koji Kawamura1, Hiroyuki Takamatsu2, Takashi Ikeda3, Tsunehiko Komatsu4, Nobuyuki Aotsuka5, Itsuto Amano6, Go Yamamoto7, Kentaro Watanabe8, Yuju Ohno9, Kosei Matsue10, Yasuji Kouzai11, Nobuhiro Tsukada12, Ken Ishiyama13, Naoyuki Anzai14, Koji Kato15, Ritsuro Suzuki16, Kazutaka Sunami17, Yoshinobu Kanda1
1Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan
2Cellular Transplantation Biology, Kanazawa University, Kanazawa, Japan
3Division of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center, Shizuoka, Japan
4Department of Hematology, Tsukuba Memorial Hospital, Tsukuba, Japan
5Division of Hematology-Oncology, Japanese Red Cross Society Narita Hospital, Narita, Japan
6Department of Hematology and Respiratory, Nara Medical University Hospital, Kashihara, Japan
7Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan
8Department of Hematology/Oncology/Infectious Diseases, Saiseikai Central Hospital, Tokyo, Japan
9Department of Internal Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan;
10Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, Kamogawa, Japan
11Department of Transfusion Medicine, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan
12Division of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
13Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan
14Department of Hematology and Oncology, Takatsuki Red Cross Hospital, Takatsuki, Japan
15Department of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan
16Department of Hematopoietic Stem Cell Transplantation Data Management/Biostatistics, Nagoya University School of Medicine, Nagoya, Japan
17Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan

Tài liệu tham khảo

Kumar, 2008, Improved survival in multiple myeloma and the impact of novel therapies, Blood, 111, 2516, 10.1182/blood-2007-10-116129 Tricot, 1996, Graft-versus-myeloma effect: proof of principle, Blood, 87, 1196, 10.1182/blood.V87.3.1196.bloodjournal8731196 Lokhorst, 2000, Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome, J Clin Oncol, 18, 3031, 10.1200/JCO.2000.18.16.3031 Crawley, 2005, Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT, Blood, 105, 4532, 10.1182/blood-2004-06-2387 Patriarca, 2012, Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability, Biol Blood Marrow Transplant, 18, 617, 10.1016/j.bbmt.2011.07.026 Passera, 2013, Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry, Biol Blood Marrow Transplant, 19, 940, 10.1016/j.bbmt.2013.03.012 Gahrton, 2013, Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study, Blood, 121, 5055, 10.1182/blood-2012-11-469452 Lokhorst, 2012, Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study, Blood, 119, 6219, 10.1182/blood-2011-11-393801 Krishnan, 2011, Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial, Lancet Oncol, 12, 1195, 10.1016/S1470-2045(11)70243-1 Giaccone, 2011, Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma, Blood, 117, 6721, 10.1182/blood-2011-03-339945 Moreau, 2008, Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma, Blood, 112, 3914, 10.1182/blood-2008-07-168823 Rosinol, 2008, A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma, Blood, 112, 3591, 10.1182/blood-2008-02-141598 Auner, 2013, Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation, Bone Marrow Transplant, 48, 1395, 10.1038/bmt.2013.73 Kharfan-Dabaja, 2013, Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials, J Hematol Oncol, 6, 2, 10.1186/1756-8722-6-2 Armeson, 2013, Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment, Bone Marrow Transplant, 48, 562, 10.1038/bmt.2012.173 Kumar, 2011, Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis, Blood, 118, 1979, 10.1182/blood-2011-02-337329 Yamada, 2004, Unrelated cord blood transplantation with a reduced-intensity conditioning regimen following autologous transplantation for multiple myeloma, Int J Hematol, 80, 377, 10.1532/IJH97.04091 Ando, 2005, Autografting followed by a reduced-intensity conditioning unrelated donor cord blood transplantation for a patient with refractory multiple myeloma: successful engraftment with minimal toxicity, Eur J Haematol, 74, 175, 10.1111/j.1600-0609.2004.00364.x Miura, 2007, Graft-versus-myeloma effects in reduced-intensity cord blood transplantation, Int J Hematol, 86, 463, 10.1007/BF02984008 Kasahara, 2009, Cord blood transplantation with a reduced-intensity conditioning regimen for patients with relapsed aggressive multiple myeloma after cytoreduction with bortezomib, Int J Hematol, 90, 413, 10.1007/s12185-009-0414-2 Eapen, 2010, Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis, Lancet Oncol, 11, 653, 10.1016/S1470-2045(10)70127-3 Atsuta, 2009, Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia, Blood, 113, 1631, 10.1182/blood-2008-03-147041 Kanda, 2013, Unrelated cord blood transplantation vs related transplantation with HLA 1-antigen mismatch in the graft-versus-host direction, Leukemia, 27, 286, 10.1038/leu.2012.203 Atsuta, 2012, Comparison of unrelated cord blood transplantation and HLA-mismatched unrelated bone marrow transplantation for adults with leukemia, Biol Blood Marrow Transplant, 18, 780, 10.1016/j.bbmt.2011.10.008 Atsuta, 2007, Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System, Int J Hematol, 86, 269, 10.1007/BF03006932 Durie, 2006, International uniform response criteria for multiple myeloma, Leukemia, 20, 1467, 10.1038/sj.leu.2404284 Przepiorka, 1995, 1994 Consensus Conference on Acute GVHD Grading, Bone Marrow Transplant, 15, 825 Sullivan, 1991, Chronic graft-versus-host disease and other late complications of bone marrow transplantation, Semin Hematol, 28, 250 Giralt, 2009, Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research, Biol Blood Marrow Transplant, 15, 367, 10.1016/j.bbmt.2008.12.497 Gooley, 1999, Estimation of failure probabilities in the presence of competing risks: new representations of old estimators, Stat Med, 18, 695, 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O Gray, 1988, A Class of K-sample tests for comparing the cumulative incidence of a competing risk, Ann Stat, 16, 1141, 10.1214/aos/1176350951 Fine, 1999, A proportional hazards model for the subdistribution of a competing risk, J Am Stat Assoc, 94, 496, 10.1080/01621459.1999.10474144 Kanda, 2013, Investigation of the freely available easy-to-use software 'EZR' for medical statistics, Bone Marrow Transplant, 48, 452, 10.1038/bmt.2012.244 Lioznov, 2010, Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells, Bone Marrow Transplant, 45, 349, 10.1038/bmt.2009.155 Attal, 2012, Lenalidomide maintenance after stem-cell transplantation for multiple myeloma, N Engl J Med, 366, 1782, 10.1056/NEJMoa1114138 McCarthy, 2012, Lenalidomide after stem-cell transplantation for multiple myeloma, N Engl J Med, 366, 1770, 10.1056/NEJMoa1114083 Kneppers, 2011, Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial, Blood, 118, 2413, 10.1182/blood-2011-04-348292 Wolschke, 2013, Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study, Exp Hematol, 41, 134, 10.1016/j.exphem.2012.10.004 Alsina, 2014, Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation, Biol Blood Marrow Transplant, 20, 1183, 10.1016/j.bbmt.2014.04.014
Thông tin
Thông tin xuất bản

Biology of Blood and Marrow Transplantation

Tập 21

1291-1298

Thông tin tác giả